The second RZV dose increased immunity against herpes zoster virus outcomes when administered within an extended window after the first dose.

EMA committee issues positive opinion to support the approval of GSK’s recombinant zoster vaccine, Shingrix in a prefilled syringe: London, UK Wednesday, October 22, 2025, 16:00 ...

Oral and inhaled biologics are gaining R&D investment due to patient acceptance and potential for home administration, with ...

The Acute Ischemic Stroke pipeline presents opportunities with 25+ drugs in development across various stages, emphasizing innovative treatments like Prourokinase recombinant, RNS60, and AVLX-144. Key ...

The drug’s success in a Phase 2 study in alpha-1 antitrypsin deficiency “validates” Sanofi’s 2024 acquisition of Inhibrx, ...

Amicus Therapeutics (FOLD) remains a Buy, driven by strong product momentum and new assets. Read here for more investment ...

Sanofi's efdoralprin alfa meets all key endpoints in a global phase II study, showing potential as a first restorative ...

The global epigenetic antibodies market size is calculated at USD 2.70 billion in 2025 and is expected to reach around USD 12.01 billion by 2034, growing at a CAGR of 18.04% for the forecasted period.

Last week, the Massachusetts Department of Public Health launched its annual seasonal vaccine public awareness campaign. The ...

CSL Seqirus real-world study finds cell-based flu vaccines offer stronger protection than egg-based options in 2023/24 season.

Sanofi’s recombinant AAT therapy, efdoralprin alfa (formerly INBRX-101), met all primary and secondary endpoints in its Phase II study. The treatment showed superiority to plasma-derived therapy and ...

The latest announcement is out from Novavax ( (NVAX) ).